PMID- 17943722
OWN - NLM
STAT- MEDLINE
DCOM- 20080122
LR  - 20220330
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 122
IP  - 3
DP  - 2008 Feb 1
TI  - EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients.
PG  - 595-602
AB  - The aim of the study was to evaluate the prognostic value of Ki-67, EZH2, MCM7 
      and EIF3S3 in prostatectomy treated patients. A retrospective population-based 
      material of 249 radical prostatectomy specimens on tissue microarrays was 
      utilized. The median follow-up of the patients was approximately 5.5 years and 
      the main end-point was biochemical progression. The expression of Ki-67, EZH2 and 
      MCM7 was determined by immunohistochemistry and the gene copy number of EIF3S3 
      was analyzed by fluorescence in situ hybridization (FISH). In the whole material, 
      increased immunostainings of EZH2, MCM7 and Ki-67 were significantly associated 
      with a high Gleason score and a short progression-free survival. In multivariate 
      analysis, MCM7 and Ki-67 showed independent prognostic value with relative risks 
      (RR) of 2.65 (95%-confidence interval of 1.22-5.70), and 1.85 (1.14-3.01), 
      respectively. In subgroup analysis of patients, whose treatment was evaluated to 
      be truly radical (n = 226), EZH2 (3.14, 1.38-7.16), MCM7 (2.70, 1.16-6.30) and 
      PSA (1.5, 1.03-2.20) showed independent prognostic value. In subgroup analysis of 
      cases with a Gleason score <7, low Ki-67 staining was associated with favorable 
      prognosis with RR of 0.09 (0.01-0.69). In conclusion, Ki-67, EZH2 and MCM7 are 
      potential prognostic biomarkers in prostatectomy treated patients.
CI  - (c) 2007 Wiley-Liss, Inc.
FAU - Laitinen, Sari
AU  - Laitinen S
AD  - Institute of Medical Technology, University of Tampere and Tampere University 
      Hospital, Tampere, Finland.
FAU - Martikainen, Paula M
AU  - Martikainen PM
FAU - Tolonen, Teemu
AU  - Tolonen T
FAU - Isola, Jorma
AU  - Isola J
FAU - Tammela, Teuvo L J
AU  - Tammela TL
FAU - Visakorpi, Tapio
AU  - Visakorpi T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Transcription Factors)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 2.1.1.43 (Polycomb Repressive Complex 2)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
RN  - EC 3.6.4.12 (MCM7 protein, human)
RN  - EC 3.6.4.12 (Minichromosome Maintenance Complex Component 7)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/metabolism
MH  - Cell Cycle Proteins/*metabolism
MH  - DNA-Binding Proteins/*metabolism
MH  - Enhancer of Zeste Homolog 2 Protein
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Ki-67 Antigen/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Minichromosome Maintenance Complex Component 7
MH  - Nuclear Proteins/*metabolism
MH  - Polycomb Repressive Complex 2
MH  - Prognosis
MH  - Prostate/metabolism
MH  - Prostate-Specific Antigen/metabolism
MH  - *Prostatectomy
MH  - Prostatic Neoplasms/*metabolism/surgery
MH  - Survival Rate
MH  - Transcription Factors/*metabolism
EDAT- 2007/10/19 09:00
MHDA- 2008/01/23 09:00
CRDT- 2007/10/19 09:00
PHST- 2007/10/19 09:00 [pubmed]
PHST- 2008/01/23 09:00 [medline]
PHST- 2007/10/19 09:00 [entrez]
AID - 10.1002/ijc.23145 [doi]
PST - ppublish
SO  - Int J Cancer. 2008 Feb 1;122(3):595-602. doi: 10.1002/ijc.23145.